aflibercept

has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders

Also Known As:

AVE 0005; AVE 005; AVE-0005; AVE-005; AVE0005; AVE005; VEGF Trap - regeneron; VEGF Trap-Eye; VEGF-Trap; ZIV-aflibercept; Zaltrap; eylea

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Membrane Proteins: 10262
    - Cell Surface Receptors: 2156
      - Receptor Protein-Tyrosine Kinases: 6127
        Vascular Endothelial Growth Factor Receptors: 3429
        aflibercept: 2075
      - Peptide Receptors: 1208
        Growth Factor Receptors: 2687
        Vascular Endothelial Growth Factor Receptors: 3429
        aflibercept: 2075
  - Recombinant Proteins: 2811
    - Recombinant Fusion Proteins: 337
      - aflibercept: 2075
  - Intracellular Signaling Peptides and Proteins: 32
    - Protein-Tyrosine Kinases: 7827
      - Receptor Protein-Tyrosine Kinases: 6127
        Vascular Endothelial Growth Factor Receptors: 3429
        aflibercept: 2075
Enzymes and Coenzymes: 1
- Enzymes: 155591
  - Transferases: 6719
    - Phosphotransferases: 43773
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9899
        Protein-Tyrosine Kinases: 7827
        Receptor Protein-Tyrosine Kinases: 6127
        Vascular Endothelial Growth Factor Receptors: 3429
        aflibercept: 2075

José Juan Escobar Selected Research

José Juan Escobar Research Topics

Disease

Drug/Important Bio-Agent (IBA)